Compare Natera Inc. Common Stock (NTRA) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while State Street SPDR S&P Homebuilders ETF trades at $92.84 (market cap $1.53B). The key difference: Natera Inc. Common Stock is far larger — about 37.3× State Street SPDR S&P Homebuilders ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and State Street SPDR S&P Homebuilders ETF for 35 Days on average.
| NTRA | XHB | |
|---|---|---|
Market Cap | $57.03B | $1.53B |
Volume | 1,131,157 | 1,987,449 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $121.36 |
52-Week Low | $179.42 | $92.84 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XHB (SPDR S&P Homebuilders ETF) trades at $94.70, up 0.69% on the day, but faces strong technical headwinds with a bearish moving average signal and key resistance at $95. The ETF reflects the homebuilding sector's sensitivity to mortgage rates, which recently hit 7%, pressuring valuations despite some positive housing data. Recent institutional activity shows mixed sentiment, with Greenland Capital adding a $17.33 million position while CoreCap Advisors reduced its stake by 99.3% in Q2 2026.
The outlook remains cautious amid high mortgage rates and mixed housing data, though potential catalysts include new housing legislation and undervalued sector signals. Risks include rate sensitivity and economic volatility, but long-term exposure to housing demand offers rebound potential. Wall Street sentiment is neutral with focus on affordability trends and policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
